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Abstract
Objective
To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r)
and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a reg-
imen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Con-
trol) in primary analysis at 48 weeks.
Design
Open label, centrally randomised trial.
Setting
Recruitment was from 37 primary and secondary care sites from Africa, Asia, Australia, Eu-
rope and Latin America.
Subjects
541 HIV-1 infected adults virologically failing first-line non-NRTI + 2N(t)RTI, with no previous
exposure to protease inhibitors or integrase strand transfer inhibitors were analysed, 425
completed 96 weeks follow up on randomised therapy.
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Intervention
Randomisation was 1:1 to Control or RAL.
Main outcomemeasures
Differences between the proportion of participants with plasma HIV-1 RNA (VL)<200 cop-
ies/mL by intention to treat were compared with a non-inferiority margin of −12%. Differ-
ences in biochemical, haematological and metabolic changes were assessed using T-tests.
Results
VL<200 copies/mL at 96 weeks was: RAL 80.4%, Control 76.0% (difference: 4.4 [95%CI −2.6,
11.3]) andmet non-inferiority criteria. The RAL arm had a significantly higher mean change (dif-
ference Control-RAL; 95%CI) in haemoglobin (−2.9; −5.7, −1.1), total lymphocytes (−0.2; −0.3,
−0.0), total cholesterol (−0.5; −0.8, −0.3), HDL cholesterol (−0.1; −0.1, −0.0) and LDL cholester-
ol (−0.3; −0.5, −0.2).
Conclusion
At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to
demonstrate similar safety profiles. These results support the use of a combination LPV/r
and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs.
Trial Registration
ClinicalTrials.gov NCT00931463
Introduction
An estimated 9.7 million people in low- and middle-income countries are now receiving antire-
troviral therapy (ART) with the number of people receiving therapy globally tripling over the
last five years [1]. With this increase in the numbers of people initiating therapy, so too there is
inevitably an increase in the number failing first-line therapy. The choice and rationale for se-
lection of second-line therapy is limited.
A recent Cochrane review suggests that there is little evidence to inform treatment guide-
lines for second-line therapy recommendations [2]. Within this setting of an acknowledged
dearth of information, the World Health Organization (WHO) recommends a boosted-prote-
ase inhibitor plus two nucleoside analogues (N(t)RTIs) as the first option for second-line thera-
py [1]. This approach maximises the use of more commonly available combination
antiretroviral therapies (cART); however it does not address the need for simple and tolerable
regimens in order to maintain long term suppressive therapy.
The Week 48 report of the SECOND-LINE trial and the Week 96 results of the EARNEST
study have reported outcomes of randomised trials that examined the safety and efficacy of ex-
perimental regimens of cART for treatment of people who were failing first line therapy[3,4].
Both studies demonstrated non-inferior outcomes for an experimental regimen of cART con-
taining raltegravir plus ritonavir-boosted lopinavir (LPV/r), a very simple regimen, compared
to 2–3N(t)RTI + LPV/r.
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Here we report the 96 week follow-up data from the SECOND-LINE trial in order to assess
the durability of treatment effects in terms of safety and efficacy of the randomised treatment
groups.
Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 Protocol and S1 CONSORT Checklist.
A full description of the methods for the SECOND-LINE trial has been previously published
[3]. In summary, SECOND-LINE was a parallel group, randomised, open-label multi-centre
international trial conducted at 37 sites across Africa, Asia, Central and South America, Aus-
tralia and Europe.
Eligible participants were adults (16 years or as per local legal requirements) positive for
HIV- 1 antibody, failing first-line therapy (non-nucleoside reverse transcriptase inhibitor
[NNRTI] plus two nucleoside/nucleotide reverse transcriptase inhibitors [N(t)RTIs]). Failure
was defined as two consecutive (>7 days apart) plasma HIV-1 RNA (VL) measures of>500
copies/mL. Patients were excluded if they had prior exposure to a protease inhibitor, an inte-
grase strand transfer inhibitor or had evidence of active viral hepatitis B infection (defined as
the presence of HBV surface antigen in serum) [3].
Participants were randomised to one of two antiretroviral regimens containing a total daily
dose of ritonavir (200 mg)-boosted lopinavir (800 mg) (LPV/r) (administered either once or
twice daily) plus either: i) two or three NtRTIs (Control); or ii) raltegravir 400 mg twice daily
(RAL). The dosing schedule (once or twice daily) for LPV/r was determined by the treating
physician. Trial visits were scheduled at Weeks 0 (randomisation) 4, 8, 12 and then every
12 weeks to Week 96. At each visit vital signs, physical health and adverse events were assessed
and blood was collected for T-cell subset counts, haematology, serum biochemistry including
renal function markers, liver function tests, metabolic markers including cholesterol fractions
(Weeks 0, 24, 48, 72 and 96 only) and plasma viral load (VL) assessment. Local assessment of
VL was used for patient management. Centrally analysed VL was used for assessment of effica-
cy. Serum collected after fasting was used for assessment of metabolic measures. Estimated glo-
merular filtration rate (eGFR) was calculated using the modification of diet in renal disease
(MDRD) equation [5]. Adherence was measured at Weeks 4, 48 and 96 using the Adult AIDS
Clinical Trials Group adherence instrument [6].
Outcomes
All outcomes in this report were assessed at Week 96. The primary endpoint of this analysis
was the proportion of participants with VL<200 copies/mL at 96 weeks. Secondary endpoints
were proportion with VL<50 copies/mL and<400 copies/mL, time to loss of virological re-
sponse and mean change from baseline in CD4+ T-cell count/mm3. Virologic failure was also
assessed and defined as a VL>200 copies/mL at any time during the trial. Clinical events (ad-
verse events, AIDS, serious non-AIDS [SNAEs], and death), mean changes in laboratory mea-
sures and adherence were also assessed. SNAEs were independently reviewed by a physician at
the Kirby Institute (Sydney, Australia) according to INSIGHT criteria [7]. Ten-year risk of cor-
onary heart disease (CHD) was determined according to the Framingham equation and meta-
bolic syndrome according to National Cholesterol Education Program Adult Treatment Panel
III [8,9]. Both these composite endpoints were only calculated for individuals who had all data
components available. There were no imputations for missing data.
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Sample size
The sample size was based on estimates expected at Week 48 of no difference between arms
and a predicted efficacy of 80% (VL<200 copies/mL). Two hundred and forty eight partici-
pants per arm gave 90% power to show non-inferiority using a margin of 12% (two sided α =
0.05) of the RAL arm compared to the Control arm in the modified intention to treat analysis.
The recruited sample size was inflated to allow for adequate power in the Week 48 per protocol
population, resulting in 541 participants being randomly assigned. This population will retain
90% power to detect non- inferiority (margin of 12%, two sided α = 0.05) if efficacy over 96
week above 71.5% is maintained.
Randomisation
Treatment arm allocation, stratified by clinical site and VL ( vs > 100,000 copies/mL), was
automated with randomisation lists built in to the electronic clinical record form. Randomi-
sation was 1:1 with a blocking factor of four. Allocation could only be triggered by the inves-
tigator aftercompletion of participant consent and entry of screening and eligibility data.
After random allocation, participants and investigators were not masked to treatment arm
allocation.
Statistical analysis
All binary virologic endpoints were assessed in three analytical populations: i) a modified in-
tention to treat (ITT) population consisting of all randomised participants who commenced
study drug and attended at least one follow-up visit- in this population deaths, loss to follow-
up and treatment change due to virologic failure were imputed as failures; ii) a per protocol
(PP); and iii) a non-completer imputed as failure (NC = F), equivalent to the FDA snapshot
analysis [10].
Change in CD4+ T cells/mm3 was assessed in the ITT population (last observation carried
forward). For other variables, summaries are provided of available data with no imputation.
All analyses were pre-specified. VL threshold analyses were assessed for non-inferiority on
the basis of 95% confidence intervals (CI) at a pre-specified margin of the lower confidence
bound of −12%. All other endpoints were tested for superiority (two side α = 0.05). The
Cochran-Mantel-Haenszel test was used to check for consistency of associations between treat-
ment arms and virological outcomes across screening VL strata.
We used χ2 and Fisher’s exact tests to analyse categorical variables; t-test for continuous var-
iables; and Cox regression for time-to-event outcomes and calculation of hazard ratios (HR).
Assessment of residual showed no evidence of violation of proportional hazards assumptions.
Logistic regression was used to test for interaction of categorical variables. SAS version 9.2 was
used for data analysis.
The study was approved by each site’s Ethics Committee under the auspices and approval of
the lead ethics/IRB of St Vincent's Hospital Sydney (Reference HREC/09/SVH/89). All partici-
pants provided direct written informed consent by signing the Participant Information and
Consent Form approved by the IRB. Where a participant was considered a minor written in-
formed consent was obtained from both the participant and their parent/guardian, the ethics
committees approved this procedure. Hard copies of the consent form are filed at the partici-
pant's relevant clinical site and a copy was given to each participant.
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Results
The study commenced recruitment in March 2010 with last participant through 96 weeks of
follow up in July 2013. The baseline characteristics of the study population were balanced be-
tween arms [3]. Participants were 55% male, 42% Asian, 36% African and 14% Hispanic, with
a mean (sd) age of 39 (8.8) years, duration of first line ART was 4.1 (2.8) years, VL was 4.2 (0.9)
log copies/mL, CD4+ T cell count was 211 (157) cells/mm3. Of the study population rando-
mised to the Control and RAL arms respectively, 245/271(90%) and 257/270(95%) reached 96
weeks of follow up, of whom 206 (84%) and 219 (85%) were on randomised therapy (Fig. 1).
At Week 96 there was no difference between arms in self-reported adherence with more than
85% of participants in each arm reporting taking “All” or “Most” of their pills.
At Week 96, 76% (206/271) in the Control and 80% (217/270) in the RAL arm reported a
VL<200 copies /mL (difference RAL-Control = 4.4%, 95%CI −2.6, 11.3) thereby satisfying our
a priori criteria for non-inferiority. Results were consistent in the PP and NC = F populations,
<50 and<400 copy thresholds, and by screening VL strata (Fig. 2). Time to loss of virologic
response did not differ between arms (Control 26.9/100 person years (py), RAL 28.1/100 py;
HR 1.1 [95% CI 0.8, 1.4]; p = 0.68). Over the first 48 weeks of the trial 55 participants in the
Control group and 49 in the RAL group had experienced virologic failure; this increased to
82 and 83 respectively over the entire 96 weeks of follow-up. The frequency of emergent resis-
tance among those who failed with an amplifiable sequence, in the Control and RAL arm, was
as follows: NtRTI 8/64 (12.5%) and 2/65 (3.1%); protease inhibitor 2/64 (3.1%) and 1/65
(1.5%); integrase strand inhibitor 1/72 (1.4%) and 20/79 (25.3%).
CD4+ T cells/mm3 increased over the whole 96 weeks in both arms (mean change from
baseline [95%CI]: 201.7 [178.6, 224.9] and 228.7 [206.6, 250.8] respectively) (Fig. 3). There was
no significant difference between arms in mean change from baseline to Week 96 (Control-
RAL −27.0 95%CI −59.0, 5.0; p = 0.10).
The differences between arms for mean change from baseline to Week 96 were statistically
significant, with greater increases in the RAL arm, for total lymphocytes, haemoglobin, total
HDL and LDL cholesterol (Table 1). Mean total cholesterol after 96 weeks of therapy was 4.9
(1.2) in the Control arm and 5.4 (1.4) in the RAL arm, with total:HDL cholesterol ratio increas-
ing up to week 4 (4.7 in both arms) before stabilizing through 96 weeks (Fig. 4). There was a
significant difference for mean change from baseline in ten-year CHD risk between arms
(mean [sd] baseline Control: 4.1 [4.7], RAL: 3.8 [4.5]) to Week 96 (Control: 4.4[4.4], RAL: 4.6
[5.1]; difference in change −0.6 95%CI −1.2, −0.1; p = 0.02).
There were no significant differences in any biochemistry, including eGFR (mean difference
−0.3 95%CI −3.1, 2.5; p = 0.834), glycaemic parameters (Table 1), nor in the proportion devel-
oping metabolic syndrome (Control: 22/238, RAL 34/253; difference −0.0% 95%CI−0.1, 0.0;
p = 0.17).
There were no differences between arms in rates of individuals ever reporting an adverse
event AIDS or death (Table 2). Of the 11 (Control) and 8 (RAL) deaths, 3 and 4 respectively oc-
curred in the last 48 weeks of follow up. A total of 66 AIDS events were reported by 53 individ-
uals. The most commonly occurring AIDS event was tuberculosis (Control 16/30, RAL 18/36)
followed by Pneumocystis jirovecii pneumonia (Control 2/30, RAL 4/36). Serious non-AIDS
events were reported by three participants in the Control arm and four in the RAL arm. Having
any clinical event (AIDS, SNAE or death) was associated with never achieving virologic sup-
pression (Odds ratio 5.8 95%CI 3.2–10.8; p =<0.001).
Grade 3/4 events were reported by 45/271 (17%) and 36/270 (13%) (p = 0.29) of individuals
in the Control and RAL arms respectively (Table 2). The greatest disparity between arms for
grade 3/4 events as summarized by system organ class was for gastrointestinal disorders which
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were reported by 7/271 (3%) and 1/270 (<0.1%) individuals in each arm respectively. Of the
grade 3/4 adverse events 8/55 in the Control arm and 13/46 in the RAL arm were attributed as
being possibly, probably or definitely related to study drugs. There was no difference in the
proportion of participants reporting adverse events associated with skeletal muscle toxicity
(Control 49/271, RAL 61/270; difference −4.5%, 95%CI −11.3, 2.13; p = 0.19). Similar
Fig 1. Participant disposition over 96 weeks.
doi:10.1371/journal.pone.0118228.g001
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Fig 2. Virologic response at Week 96, by randomised arm, study population and screening strata.RAL = lopinavir/ritonavir+raltegravir Control =
lopinavir/ritonavir+2/3 nucleoside/nucleotide reverse transcriptase inhibitors. *grey circle = screening plasma viral load strata, P interaction = 0.81, bars are
95%confidence intervals (CI).
doi:10.1371/journal.pone.0118228.g002
Fig 3. Mean change from baseline in CD4+ T cells/mm3 over 96 weeks by randomised arm. RAL = lopinavir/ritonavir+raltegravir Control = lopinavir/
ritonavir+2/3 nucleoside/nucleotide reverse transcriptase inhibitors. (Control- - - RAL—, bars indicate standard deviation).
doi:10.1371/journal.pone.0118228.g003
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proportions of participants reported ceasing antiretroviral therapy due to an adverse event
(Control 12/46, RAL 9/45).
Discussion
We have shown that over 96 weeks participants who have previously failed first line ART con-
sisting of NNRTI + 2 N(t)RTIs and then commence a regimen of LPV/r with RAL or LPV/r +
2–3N(t)RTI, achieve and maintain VL suppression rates greater than 75%. This finding, as it
relates to the N(t)RTI-containing arm, supports therapy guidelines as stated by the WHO. We
also demonstrate that a regimen containing LPV/r + RAL provides a non-inferior alternative
to currently recommended therapy in a second-line setting [1].
Our study was conducted in diverse settings across high, middle and low income countries,
with a high proportion of females and included homosexual and heterosexual participants.
Thus the findings from our study are likely to be highly generalizable across similar popula-
tions. While our study was not blinded, the primary endpoint, VL, was objective and centrally
analysed and thus unlikely to be subject to biased assessment. Randomisation was also central
and electronic and the well-balanced characteristics between arms suggests that allocation was
random and there is no indication of confounding from measured covariates [3]. However, it is
possible that patient management or participant reporting of self-assessed outcomes may have
been influenced by the open label nature of this trial.
At Week 48, a statistically significant difference in mean change from baseline CD4+ T-
cells/mm3 was noted between treatment arms [3], however this difference abated by 96 weeks.
This finding may have resulted from sicker people leaving the trial. Alternatively there may
Table 1. Differences in mean change from baseline to Week 96 in laboratory markers by randomised arm.
Control RAL Difference (Control-RAL)
Mean SD Mean SD 95%CI p-value
Immunology and haematology
CD4+ T (cells/mm3) 201.7 193.7 228.7 184.6 −27.0 (−59.0, 5.0) 0.100
Total lymphocytes (cells/mm3) 0.5 0.7 0.7 0.7 −0.2 (−0.3, −0.0) 0.018
Neutrophils(cells/mm3) 0.8 1.4 0.9 1.4 −0.1 (−0.3, 0.2) 0.452
Haemoglobin (g/L) 5.5 17.2 8.3 14.7 −2.9 (−5.7, −0.1) 0.046
Biochemistry
ALT (U/L) −11.1 25.4 −6.6 32.9 −4.5 (−9.7, 0.7) 0.091
Creatine kinase (U/L) −13.7 203.3 −14.9 193.1 1.3 (−33.8, 36.4) 0.943
eGFR (mL/min/1.73m2) −5.5 16.5 −5.2 14.7 −0.3 (−3.1, 2.5) 0.834
Metabolic parameters
Total cholesterol (mmol/L) 0.4 1.2 0.9 1.2 −0.5 (−0.8, −0.3) <0.001
HDL choletersol (mmol/L) 0.0 0.4 0.1 0.4 −0.1 (−0.1, −0.0) 0.003
Total:HDL cholesteol ratio 0.4 1.3 0.5 1.5 −0.2 (−0.4, 0.1) 0.204
LDL cholesterol (mmol/L) 0.2 0.8 0.5 0.9 −0.3 (−0.5, −0.2) <0.001
Triglycerides (mmol/L) 0.8 1.9 1.0 1.8 −0.1 (−0.5, 0.2) 0.417
Glycaemic parameters
Glucose (mmol/L) −0.1 1.4 0.2 1.8 −0.3 (−0.5, 0.0) 0.090
Insulin (mU/L) −0.9 16.3 0.6 14.4 −1.6 (−4.3, 1.2) 0.267
HOMA −0.3 5.5 0.4 4.6 −0.7 (−1.6, 0.2) 0.128
eGFR: estimated glomerular ﬁltration rate, LDL: low density lipoprotein, HDL: high density lipoprotein, HOMA: homeostasis model assessment
doi:10.1371/journal.pone.0118228.t001
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have been a further improvement in patient health, with both arms showing a greater than
50 cell/mm3 increase in the latter 48 weeks of the trial.
Both trial regimens were well tolerated with the vast majority of participants staying in fol-
low-up, on randomised therapy and adherent. Comparable tolerance is supported by the equal
frequency of virologic failure in each arm. The predictors of failure and the role of emergent re-
sistance, particularly integrase strand inhibitor resistance in the RAL arm, require further in-
vestigation. In the Control arm, mean change in haemoglobin and total lymphocyte count
were significantly lower than in the RAL arm. Associations between thymidine-containing reg-
imens and haematological changes have previously been reported [11], we therefore conducted
a pre-specified exploratory analysis restricted to those not on zidovudine-containing regimens
in the Control arm compared to the RAL arm. This analysis showed substantial attenuation of
the difference in change from baseline in haemoglobin and lymphocytes, such that there was
no significant difference between groups. This finding should, however, be interpreted with
caution as it is not a true randomised comparison. We found no decrement in the Control arm
in terms of eGFR. 253 of 271 (93%) of participants in the Control arm were tenofovir contain-
ing regimens, which have been found to result in greater decreases in cohort studies and some
but not all switch studies [12–15].
The elevations in total LDL and HDL cholesterol in the RAL arm reported here are consis-
tent with the findings reported at Week 48. It appears that total cholesterol in the RAL arm
may be continuing to marginally increase at a higher rate than the Control arm. This may be
partially due to high exposure to tenofovir in the Control arm which has been shown to have a
beneficial impact on lipids [3,16]. However these findings occur in the presence of no differ-
ence between arms in total:HDL ratio. How the lipid profiles translate to clinical risk is difficult
to ascertain. The mean total cholesterol in the RAL population (5.4mmol/L) is within the
Fig 4. Absolute mean cholesterol fractions and ratio over 96 weeks by randomised arm. (A) total cholesterol, (B) high density lipoprotein (HDL)
cholesterol, (C) low density lipoprotein (LDL) cholesterol, (D) Total:HDL cholesterol ratio. RAL = lopinavir/ritonavir+raltegravir Control = lopinavir/ritonavir+2/3
nucleoside/nucleotide reverse transcriptase inhibitors. (Control - - - RAL—, bars indicate standard deviation).
doi:10.1371/journal.pone.0118228.g004
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moderate risk estimation for an individual in the general population [8]. While those in the
RAL arm were at significantly greater risk for CHD than in the Control arm, their mean abso-
lute ten year risk at the end of study was 4.6%. Recent guidelines, in contrast to Framingham,
are also moving away from threshold based assessment of risk to a more holistic individual
based risk assessment [8,17]. Poorer lipid outcomes have not been reported in other extended
follow up randomised trials of RAL containing regimens [18,19].
After 96 weeks of follow up, our study showed both continued efficacy of the RAL-contain-
ing regimen, and non-inferiority compared to Control, in the treatment of HIV following first-
line failure. This outcome and the overall adverse events profile are consistent with the prelimi-
nary 96 week data from comparative arms in the EARNEST trial[4]. While EARNEST was set
in low income countries and SECOND LINE in predominantly middle income countries, both
trials demonstrate non-inferior efficacy of a simple RAL based therapy with high tolerability.
Given the broad setting of these studies the results bode well for the effectiveness of Control
and RAL regimens. However detailed results from other trials are required to determine wheth-
er RAL consistently results in an increase in cholesterol and if so the consequential long term
risks. There were very low levels of emergent PI resistance in either arm of the trial and moder-
ate NtRTI and integrase strand inhibitor resistance in the Control and RAL arms respectively.
Further investigations are currently underway exploring the relationships between resistance,
virological failure and adherence.
Table 2. Clinical outcomes by randomised arm.
Control (N = 271) RAL (N = 270) Hazard Ratio 95%CI p-value
n Rate/100 py n Rate/100 py
Deaths 11 2.4 8 1.6 0.7 (0.3, 1.8) 0.456
AIDS or death 29 6.6 34 7.6 1.2 (0.7, 1.9) 0.538
Serious adverse events 33 7.4 40 8.8 1.2 (0.8, 1.9) 0.456
Adverse events 1391 297.2 1387 285.0 0.9 (0.8, 1.1) 0.238
Number of participants reporting Grade 3/4 adverse events* n % n %
Number of Grade 3/4 adverse events
Total 45 16.6 36 13.3
55 46
Infections and infestations 11 4.1 7 2.6
12 13
General disorders and administration site conditions 4 1.5 5 1.9
4 5
Gastrointestinal disorders 7 2.6 1 0.4
9 1
Blood and lymphatic system disorders 4 1.5 3 1.1
10 3
Metabolism and nutrition disorders 2 0.7 3 1.1
2 5
Pregnancy, puerperium and perinatal conditions 2 0.7 3 1.1
2 4
Ceased antiretroviral therapy due to any grade adverse event 12/46 26.1 9/45 20.0
*Grade 3/4 adverse events summarised by MedDRA System Organ Class which were reported by 5 or more people
py: person years
doi:10.1371/journal.pone.0118228.t002
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At current prices RAL containing regimens are unlikely to provide a cost effective alterna-
tive to standard of care in low income countries. This is likely to be the case until price reduc-
tions and generic options become available. However RAL use may provide a viable and
durable alternative for second-line therapy in middle and high income countries, and for pa-
tients unable to receive NRTI-based regimens.
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